MD PhD David A. Hilton

Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2

D. Evans, C. Hanemann, D. Hilton, 2019, Journal of Neurology, Neurosurgery, and Psychiatry.